Alkem Pharma Unit Signs Fresh Pact to Move Closer to Swiss Medtech Acquisition

Synopsis: Alkem Laboratories’ wholly owned subsidiary Alkem Medtech Private Limited has executed a First Supplementary Agreement to its Share Purchase Agreement for acquiring a controlling 51 – 55% stake in Occlutech Holding AG, a Switzerland-incorporated cardiac structural implant company. The amendment moves the acquisition meaningfully closer to completion, marking Alkem’s most significant push into the global medical devices space.

India’s major pharmaceutical companies are moving beyond traditional medicines into the high-profit world of medical technology. A key target is heart implants that fix defects without open-heart surgery, a fast-growing market as doctors shift to these less invasive procedures. For an Indian pharma giant looking to go global, buying a controlling stake in an established European implant manufacturer is the fastest way to gain top-tier products and immediate access to international markets.

What’s the News?

Alkem Laboratories Limited has disclosed, pursuant to Regulation 30 of the SEBI Listing Regulations, that its wholly owned Indian subsidiary Alkem Medtech Private Limited executed a First Supplementary Agreement to the Share Purchase Agreement dated March 6, 2026 with the selling shareholders of Occlutech Holding AG, a company incorporated in Switzerland. 

This supplementary agreement was executed on June 26, 2026. The original transaction, first disclosed to stock exchanges on February 13, 2026, involved Alkem Medtech’s intention to acquire at least 51% and up to 55% of the total issued equity share capital of Occlutech.

The supplementary agreement represents a formal amendment to the original SPA, typically used to revise deal terms, timelines, representations, or conditions precedent, and signals active progression toward transaction close.

Occlutech is a Switzerland-headquartered medical device company specialising in structural heart defect closure implants, including devices for patent foramen ovale (PFO), atrial septal defect (ASD), and ventricular septal defect (VSD) closures used in minimally invasive cardiac procedures. Its products are commercially deployed across European and international markets.

The strategic purchase of Occlutech gives Alkem immediate access to major international markets like Europe and the US. This smart move allows the company to entirely bypass years of expensive regulatory hurdles and instantly gain vital relationships with global hospitals.

Advanced structural heart implants carry premium pricing due to their complex nature and limited competition. This high-margin segment protects Alkem’s overall profits from the heavy price cuts and revenue erosion that frequently impact the traditional generic medicine industry.

This acquisition officially transforms Alkem from a basic generic drug manufacturer into a diversified, global healthcare leader. By adding an advanced medical technology platform to its business, the company is well-positioned to capture massive long-term growth worldwide.

A controlling stake of 51–55% in Occlutech will bring the Swiss company’s financials into Alkem’s consolidated accounts upon deal closure, adding medtech revenues, assets, and liabilities to the group balance sheet. While the upfront €99.4 million price tag demands an immediate deployment of cash reserves, the long-term cash flow from a high-margin interventional cardiology portfolio is expected to enhance return metrics over the medium term.

Following the latest market activity, shares of Alkem Laboratories Limited rose 0.76% in Monday morning trade, exchanging hands at ₹5,466.50. The pharmaceutical major currently commands a market capitalization of approximately ₹65,360.21 crore and is trading at a trailing P/E ratio of 27.56.

Company Overview

Incorporated in 1973 and headquartered in Mumbai, Alkem Laboratories Limited is one of India’s leading pharmaceutical companies, with a strong presence in branded generics, acute therapies, and chronic disease management. The company markets products across anti-infective, gastrointestinal, pain management, vitamins, and cardiac therapeutic segments, supported by an extensive domestic distribution network. Through its subsidiaries, Alkem has expanded into international generic markets and, with the Occlutech acquisition, is broadening its presence into global medical devices.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Alkem Pharma Unit Signs Fresh Pact to Move Closer to Swiss Medtech Acquisition appeared first on Trade Brains.